Skip to main content

New Drug Approvals 2012 - Pt. XXIX - Pasireotide diaspartate (SIGNIFOR®)


ATC code: H01CB05
Wikipedia: Pasreotide

On December 14, the FDA approved Pasireotide diaspartate (SIGNIFOR®, Research CodeL SOM-230, CAS# 396091-73-9, Pub-Chem : CID 9941444, KEGG : D10147), a cyclohexide with pharmacologic properties mimicking those of natural hormone Somatostatin for treatment of adult patients with Cushing's disease (CD) for whom pituitary surgery is not an option or has not been curative.

Cushing's disease (CD) is a cause of Cushing's syndrome characterised by increased secretion of ACTH (adrenocorticotropic hormone) from the anterior pituitary. CD is a rare hormone disorder, and  recent statistics indicate that the annual incidence is somewhere between 1 and 10 per million and is 3 times more common in women than in men (from NEMDIS). This is most often as a result of pituitary adenoma or due to excess production of hypothalamus Corticotropin releasing hormone (CRH). More information can be found in Medscape.


The therapeutic activity of Pasireotide diaspartate is through binding to Somatostatin receptors (SSTRs). They belong to GPCR class of targets and there are five known SSTRs in human: SSTR1 (CHEMBL1917P30872), SSTR2 (CHEMBL1804P30874), SSTR3 (CHEMBL2028P32745), SSTR4 (CHEMBL1853P31391) and SSTR5 (CHEMBL1792P35346). These receptor subtypes are expressed in different tissues under normal physiological condition. Corticotroph tumor cells from CD patients frequently over express SSTR5, whereas the other receptor subtypes are often not expressed or expressed at lower levels. Pasireotide diaspartate has a 40-fold increased affinity to SSTR5 than other SSTR analogs binds and activates the receptors resulting in inhibition of ACTH secretion, which leads to decreased cortisol secretion.


Since the targets of this drug belong to same family of receptors (somatostatin receptors), multiple  sequence alignment of human SSTR1, 2, 3, 4 and 5 receptors was done using T-coffee which is shown above. The protein sequences (fasta format) of human SSTR1, 2, 3, 4 and 5 can be downloaded from this link here. (courtesy UniProt)


Standard InChI : 1/C58H66N10O9/c59-27-13-12-22-46-52(69)64-47(30-38-23-25-42(26-24-38)76-36-39-16-6-2-7-17-39)53(70)66-49(31-37-14-4-1-5-15-37)57(74)68-35-43(77-58(75)61-29-28-60)33-50(68)55(72)67-51(40-18-8-3-9-19-40)56(73)65-48(54(71)63-46)32-41-34-62-45-21-11-10-20-44(41)45/h1-11,14-21,23-26,34,43,46-51,62H,12-13,22,27-33,35-36,59-60H2,(H,61,75)(H,63,71)(H,64,69)(H,65,73)(H,66,70)(H,67,72)/t43-,46+,47+,48-,49+,50+,51+/m1/s1/f/h61,63-67H

Smiles : NCCCC[C@H]1C(N[C@H](C(N[C@H](C(N2[C@H](C(N[C@H](C(N[C@@H](C(N1)=O)CC1=CNC3=CC=CC=C13)=O)C1=CC=CC=C1)=O)C[C@H](C2)OC(NCCN)=O)=O)CC2=CC=CC=C2)=O)CC2=CC=C(C=C2)OCC2=CC=CC=C2)=O
Iupac Name : (2-Aminoethyl) carbamic acid (2R,5S,8S,11S,14R,17S,19aS)-11-(4-aminobutyl)-5-benzyl-8-(4-benzyloxybenzyl)-14-(1H-indol-3-ylmethyl)-4,7,10,13,16,19-hexaoxo-17-phenyloctadecahydro-3a,6,9,12,15,18-hexaazacyclopentacyclooctadecen-2-yl ester, di[(S)-2-aminosuccinic acid] salt


Pasireotide diaspartate is a Somatostatin analog and is cyclohexapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. The recommended dosage range of Pasireotide diaspartate is 0.3 to 0.9 mg administered as subcutaneous injection twice a day.

Pasireotide diaspartate demonstrates approximately linear pharmacokinetics for a dose range from 0.0025 to 1.5 mg in healthy patients with dose proportional Cmax and AUC and Tmax of 0.25 to 0.5 hrs. Apparent volume of distribution (Vz/F) was >100 L with plasma concentration of about 91%. Plasma protein binding was moderate (88%). It is shown to be metabolically stable in human liver and kidney and is eliminated mainly via hepatic clearance.

Full prescribing information can be found here.

The license holder is Novartis Pharmaceuticals, and the product website is www.signifor.com.

Comments

Popular posts from this blog

Improvements in SureChEMBL's chemistry search and adoption of RDKit

    Dear SureChEMBL users, If you frequently rely on our "chemistry search" feature, today brings great news! We’ve recently implemented a major update that makes your search experience faster than ever. What's New? Last week, we upgraded our structure search engine by aligning it with the core code base used in ChEMBL . This update allows SureChEMBL to leverage our FPSim2 Python package , returning results in approximately one second. The similarity search relies on 256-bit RDKit -calculated ECFP4 fingerprints, and a single instance requires approximately 1 GB of RAM to run. SureChEMBL’s FPSim2 file is not currently available for download, but we are considering generating it periodicaly and have created it once for you to try in Google Colab ! For substructure searches, we now also use an RDKit -based solution via SubstructLibrary , which returns results several times faster than our previous implementation. Additionally, structure search results are now sorted by

ChEMBL brings drug bioactivity data to the Protein Data Bank in Europe

In the quest to develop new drugs, understanding the 3D structure of molecules is crucial. Resources like the Protein Data Bank in Europe (PDBe) and the Cambridge Structural Database (CSD) provide these 3D blueprints for many biological molecules. However, researchers also need to know how these molecules interact with their biological target – their bioactivity. ChEMBL is a treasure trove of bioactivity data for countless drug-like molecules. It tells us how strongly a molecule binds to a target, how it affects a biological process, and even how it might be metabolized. But here's the catch: while ChEMBL provides extensive information on a molecule's activity and cross references to other data sources, it doesn't always tell us if a 3D structure is available for a specific drug-target complex. This can be a roadblock for researchers who need that structural information to design effective drugs. Therefore, connecting ChEMBL data with resources like PDBe and CSD is essen

Improved querying for SureChEMBL

    Dear SureChEMBL users, Earlier this year we ran a survey to identify what you, the users, would like to see next in SureChEMBL. Thank you for offering your feedback! This gave us the opportunity to have some interesting discussions both internally and externally. While we can't publicly reveal precisely our plans for the coming months (everything will be delivered at the right time), we can at least say that improving the compound structure extraction quality is a priority. Unfortunately, the change won't happen overnight as reprocessing 167 millions patents takes a while. However, the good news is that the new generation of optical chemical structure recognition shows good performance, even for patent images! We hope we can share our results with you soon. So in the meantime, what are we doing? You may have noticed a few changes on the SureChEMBL main page. No more "Beta" flag since we consider the system to be stable enough (it does not mean that you will never

ChEMBL 34 is out!

We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains:         2,431,025 compounds (of which 2,409,270 have mol files)         3,106,257 compound records (non-unique compounds)         20,772,701 activities         1,644,390 assays         15,598 targets         89,892 documents Data can be downloaded from the ChEMBL FTP site:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/ Please see ChEMBL_34 release notes for full details of all changes in this release:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/chembl_34_release_notes.txt New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding vaccines). 71 out of the 882 newly added EMA drugs are only authorised by EMA, rather than from other regulatory bodies e.g.

New SureChEMBL announcement

(Generated with DALL-E 3 ∙ 30 October 2023 at 1:48 pm) We have some very exciting news to report: the new SureChEMBL is now available! Hooray! What is SureChEMBL, you may ask. Good question! In our portfolio of chemical biology services, alongside our established database of bioactivity data for drug-like molecules ChEMBL , our dictionary of annotated small molecule entities ChEBI , and our compound cross-referencing system UniChem , we also deliver a database of annotated patents! Almost 10 years ago , EMBL-EBI acquired the SureChem system of chemically annotated patents and made this freely accessible in the public domain as SureChEMBL. Since then, our team has continued to maintain and deliver SureChEMBL. However, this has become increasingly challenging due to the complexities of the underlying codebase. We were awarded a Wellcome Trust grant in 2021 to completely overhaul SureChEMBL, with a new UI, backend infrastructure, and new f